Transderm scopolamine efficacy related to time of application prior to the onset of motion.
We evaluated Transdermal Scopolamine related to the time of application prior to the onset of motion. In this study 44 subjects participated. The first group applied the transdermal disc within 4 h and the second group 8 h or more prior to the onset of motion. We observed a significant decrease in the incidence and the degree of motion sickness for the group with at least 8 h of scopolamine application prior to sea travel. Therefore, the transdermal scopolamine system should be applied at least 8 h before potentially disturbing motion to provide adequate prophylaxis against motion sickness. We found no significant difference in motion sickness susceptibility between men and women, in contrast to earlier reports.
D000287:Administration, Topical; D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009041:Motion Sickness / Q000517:prevention & control*; D012601:Scopolamine / Q000008:administration & dosage / Q000627:therapeutic use*; D012737:Sex Factors; D013997:Time Factors
D012601:Scopolamine